What is the 13F Pro Quality Score for ANGO?

13F Pro ranks ANGIODYNAMICS INC (ANGO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ANGO's current score at https://13fpro.ai/research/ANGO (free sign-up required for the full ranking).

Where does 13F Pro source ANGO data?

All ANGIODYNAMICS INC fundamentals and ownership data come directly from SEC EDGAR. ANGIODYNAMICS INC files with the SEC under CIK 1275187. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ANGO in?

ANGIODYNAMICS INC (ANGO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ANGO research updated on 13F Pro?

ANGO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ANGIODYNAMICS INC(ANGO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1275187 ANGO stock profile & AI dashboard →

13F Pro Quality Score

26.9/100

Rank #2,498 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

36.1/100

Profitability

22.8/100

Balance Sheet

15.3/100

Earnings Quality

30.0/100

Free Cash Flow

25.6/100

Institutional Flow

27.1/100

Revenue Scale

30.9/100

Dilution Risk

29.0/100

ANGO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ANGIODYNAMICS INC (ANGO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANGO at 26.9/100 on a 32-signal composite quality model, placing it at rank #2,498 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (15.3) and profitability (22.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2026), ANGIODYNAMICS INC reports quarterly revenue of $86.6M, net income of $-11.4M, an operating margin of -11.8%. Top institutional holders of ANGO by reported 13-F value include BlackRock,, Point72 Asset Management, L.P., SYSTEMATIC FINANCIAL MANAGEMENT, based on the most recent SEC filings. ANGO trades on the Nasdaq exchange and files with the SEC under CIK 1275187. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANGO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANGIODYNAMICS INC directly from SEC EDGAR. ANGIODYNAMICS INC's 13F Pro composite quality score has ranged between 8 and 45 since 2021, currently 26.9 — a stable long-term trajectory across 57 quarterly and live scoring snapshots.

✦

Fun facts about ANGIODYNAMICS INC

Quirks, history, and lore behind ANGO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in upstate New York.
2
The Numbers
Annual revenue in the range of $300–400 million — not a giant, but a focused player serving hospitals and interventional specialists across the globe.
3
The History
Founded in the 1980s and built through decades of acquisitions, it carved out a niche in minimally invasive medical procedures targeting the vascular system.
4
The Secret
Its portfolio is laser-focused on venous and oncology applications — think devices that zap, drain, or clear things inside your blood vessels and tumors.
5
The Lore
It makes tools for ablation, thrombus management, and drainage — the unglamorous plumbing work that keeps interventional radiology suites humming every day.
6
The Giveaway
Its very name is a mashup of angio (blood vessels) and dynamics — and its ticker, ANGO, makes it pretty hard to hide.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q4 2026

$86.6M

Net Income

Q4 2026

$-11.4M

Free Cash Flow

Q4 2026

$17.0M

Operating Margin

Q4 2026

-11.8%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+9.5% YoY

$320.2MFY 2026

FY22 $316.2MFY24 $303.9MFY25 $292.5MFY26 $320.2M

Net Income

-8.1% YoY

$-36.7MFY 2026

FY22 $-26.5MFY24 $-184.3MFY25 $-34.0MFY26 $-36.7M

Operating Income

+0.1% YoY

$-39.9MFY 2026

FY22 $-28.5MFY24 $-192.4MFY25 $-40.0MFY26 $-39.9M

EPS (Diluted)

-6.0% YoY

$-0.88FY 2026

FY22 $-0.68FY24 $-4.59FY25 $-0.83FY26 $-0.88

Total Assets

-4.6% YoY

$267.2MFY 2026

FY22 $552.8MFY24 $317.7MFY25 $280.1MFY26 $267.2M

Total Debt

—FY 2026

FY22 $25.0MFY24 $0.00FY25 —FY26 —

Op. Cash Flow

+130.5% YoY

$3.1MFY 2026

FY22 $-7.2MFY24 $-28.2MFY25 $-10.1MFY26 $3.1M

Metric	FY 2026	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Revenue	$320.2M +9.5%	$292.5M -3.8%	$303.9M -3.9%	$316.2M +8.7%	$291.0M +10.2%	$264.2M
Net Income	$-36.7M -8.1%	$-34.0M +81.6%	$-184.3M -594.4%	$-26.5M +15.9%	$-31.5M +81.1%	$-166.8M
Operating Income	$-39.9M +0.1%	$-40.0M +79.2%	$-192.4M -575.9%	$-28.5M +19.3%	$-35.3M +78.9%	$-167.1M
EPS (Diluted)	$-0.88 -6.0%	$-0.83 +81.9%	$-4.59 -575.0%	$-0.68 +17.1%	$-0.82 +81.3%	$-4.39
Total Assets	$267.2M -4.6%	$280.1M -11.8%	$317.7M -42.5%	$552.8M -1.5%	$561.4M -5.5%	$594.2M
Total Debt	—	—	$0.00 -100.0%	$25.0M	—	$0.00
Operating Cash Flow	$3.1M +130.5%	$-10.1M +64.0%	$-28.2M -291.4%	$-7.2M -129.9%	$24.1M +265.5%	$-14.6M

Get alerted when ANGO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ANGIODYNAMICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ANGO

BlackRock, Inc.
$41.9M3,685,904 sh
Point72 Asset Management, L.P.
$36.2M3,181,829 sh
SYSTEMATIC FINANCIAL MANAGEMENT LP
$27.9M2,453,701 sh
Broadfin Holdings LLC
$23.5M2,069,333 sh
ARMISTICE CAPITAL, LLC
$21.3M1,869,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$19.6M1,726,820 sh
ROYCE & ASSOCIATES LP
$17.4M1,528,951 sh
WEBER CAPITAL MANAGEMENT LLC /ADV
$15.6M1,373,149 sh
STATE STREET CORP
$15.2M1,333,858 sh
Bastion Asset Management Inc.
$14.1M1,313,002 sh

Fund	Value	Shares
BlackRock, Inc.	$41.9M	3,685,904
Point72 Asset Management, L.P.	$36.2M	3,181,829
SYSTEMATIC FINANCIAL MANAGEMENT LP	$27.9M	2,453,701
Broadfin Holdings LLC	$23.5M	2,069,333
ARMISTICE CAPITAL, LLC	$21.3M	1,869,000
VANGUARD CAPITAL MANAGEMENT LLC	$19.6M	1,726,820
ROYCE & ASSOCIATES LP	$17.4M	1,528,951
WEBER CAPITAL MANAGEMENT LLC /ADV	$15.6M	1,373,149
STATE STREET CORP	$15.2M	1,333,858
Bastion Asset Management Inc.	$14.1M	1,313,002

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ANGO on your watchlist

Track score changes the day ANGIODYNAMICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ANGO a good stock to buy?

13F Pro's AI-powered analysis of ANGIODYNAMICS INC (ANGO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANGO are available on the ANGO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ANGO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANGO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ANGIODYNAMICS INC's investment landscape.